These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30941773)

  • 1. Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model.
    Golchin S; Alimohammadi R; Rostami Nejad M; Jalali SA
    J Cell Physiol; 2019 Nov; 234(11):19866-19874. PubMed ID: 30941773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
    Limagne E; Thibaudin M; Nuttin L; Spill A; Derangère V; Fumet JD; Amellal N; Peranzoni E; Cattan V; Ghiringhelli F
    Cancer Immunol Res; 2019 Dec; 7(12):1958-1969. PubMed ID: 31611243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
    Gou HF; Huang J; Shi HS; Chen XC; Wang YS
    PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmented Antitumor Effect of Unripe
    Lee EJ; Yang JH; Choi JG; Chung HS
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.
    Song W; Shen L; Wang Y; Liu Q; Goodwin TJ; Li J; Dorosheva O; Liu T; Liu R; Huang L
    Nat Commun; 2018 Jun; 9(1):2237. PubMed ID: 29884866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
    Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
    Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
    Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R
    Front Immunol; 2023; 14():1085476. PubMed ID: 36960067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
    Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
    Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
    Fransen MF; Schoonderwoerd M; Knopf P; Camps MG; Hawinkels LJ; Kneilling M; van Hall T; Ossendorp F
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer.
    Wang Q; Wang Z; Wu Y; Klinke DJ
    BMC Cancer; 2020 Jan; 20(1):26. PubMed ID: 31914948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
    Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
    Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
    Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
    Shindo Y; Yoshimura K; Kuramasu A; Watanabe Y; Ito H; Kondo T; Oga A; Ito H; Yoshino S; Hazama S; Tamada K; Yagita H; Oka M
    Anticancer Res; 2015 Jan; 35(1):129-36. PubMed ID: 25550543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of SiRNA-PD-L1 by attenuated Salmonella in combination with oxaliplatin in a hepatocellular carcinoma mouse model.
    Chen P; Chen J; Li B; Zhang Y; Li K; Shao C; Guo P; Yang T; Liu H; Jia X; Duan X; Zhao T; Jia H; Ren J
    Int Immunopharmacol; 2024 Nov; 141():112892. PubMed ID: 39146787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.